Enlivex rises on US patent for cell therapy

Enlivex

19/04/2023 14:52

** U.S.-listed shares of Enlivex Therapeutics Ltd  ENLV.O 
rise 3.45% to $3  
    ** Co says it has been granted a U.S. patent covering
methods of using its experimental cell therapy to treat tumors  
    ** The off-the-shelf cell therapy candidate, allocetra, is
designed to reprogram a type of white blood cells to regain
their steady state in cases of diseases such as solid cancers,
sepsis and COVID-19 - ENLV       
    ** The patent will extend the drug's intellectual property
protection through at least 2036 - ENLV 
    ** Including session gains, stock down ~24% YTD 

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))